EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Early taxane exposure and neurotoxicity in breast cancer patients

Erika Cimbro, Mariele Dessì, Pina Ziranu, Clelia Madeddu, Francesco Atzori, Eleonora Lai, Andrea Pretta, Stefano Mariani, Clelia Donisi, Dario Spanu, Marta Pozzari, Sara Murgia und 8 weitere

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08908-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Erika Cimbro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy. erikacimbro@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Quality of Life, Neurotoxicity Syndromes, Paclitaxel. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Cagliari.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Breast cancer is the most diagnosed tumor and a leading cause of cancer death in women worldwide. Taxanes are the most used chemotherapeutic agents and are strictly connected to neurotoxicity. Taxane-induced neuropathy (TIN) significantly impacts patients’ quality of life (QOL). Early identification and management of TIN could improve preventive strategies to preserve patients’ QOL during and after breast cancer treatment.

Objective

This prospective, observational study aimed to evaluate the taxane-induced neuropathy (TIN) in early breast cancer patients treated with weekly paclitaxel at an earlier stage and identify any correlation between TIN and QOL.

Methods

Data from stage I-III breast cancer patients treated with taxane-based therapy between 2018 and 2022 were collected at the Medical Oncology Unit of the University Hospital of Cagliari. Peripheral neuropathy was evaluated using the NCI-CTCAE scale (National Cancer Institute, Common Terminology Criteria for Adverse Events) at every drug administration. In contrast, QOL was assessed using EORTC QLC-CIPN20 and FACT-Taxane questionnaire at baseline (T0), after 4 weeks (T1) and 12 (T2) weeks of treatment. Statistical analysis was performed to evaluate the correlation between neurotoxicity and QOL.

Results

Neurotoxicity incidence peaked at the third, fourth, and sixth week of treatment, with patients reporting grade 1 and 2 neurotoxicity. Simultaneously with increasing doses of paclitaxel, significant differences in QOL were observed in early treatment cycles relating to TIN presentation. Patients with higher neurotoxicity grades reported lower QOL scores.

Conclusions

Despite the absence of effective treatments to prevent paclitaxel-induced neurotoxicity, symptoms are managed through dosage reduction, delay, or treatment interruption. Future research should focus on identifying neuroprotective measures to avoid an irreversible decline in the quality of life for breast cancer survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsQuality of LifeNeurotoxicity SyndromesPaclitaxelPeripheral Nervous System DiseasesHumansFemaleMiddle AgedProspective StudiesAgedAdultTaxoidsAntineoplastic Agents, PhytogenicBridged-Ring Compounds

Stichwörter der Autor:innen

NeurotoxicityQuality of lifeTaxane

Substanzen

PaclitaxelTaxoidsAntineoplastic Agents, PhytogenictaxaneBridged-Ring Compounds

Autor:innen und Institutionen

  • Medical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy. erikacimbro@gmail.com.
  • Medical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
  • Department of Medical Sciences and Public Health, University of Cagliari, 09042, Cagliari, Italy.
  • Department of Anesthesia, Resuscitation and Pain Therapy, University of Cagliari, 09042, Cagliari, Italy.

Förderung

  • Università degli Studi di Cagliari

Zitieren

APA

Cimbro, E., Dessì, M., Ziranu, P., Madeddu, C., Atzori, F., Lai, E., Pretta, A., Mariani, S., Donisi, C., Spanu, D., Pozzari, M., Murgia, S., Saba, G., Codipietro, C., Palmas, E., Sanna, G., Semonella, F., Sardo, S., Finco, G., & Scartozzi, M. (2024). Early taxane exposure and neurotoxicity in breast cancer patients. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08908-2

Vancouver

Cimbro E, Dessì M, Ziranu P, Madeddu C, Atzori F, Lai E, et al. Early taxane exposure and neurotoxicity in breast cancer patients. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08908-2

BibTeX
@article{Cimbro2024,
  author = {Cimbro, Erika and Dessì, Mariele and Ziranu, Pina and Madeddu, Clelia and Atzori, Francesco and Lai, Eleonora and Pretta, Andrea and Mariani, Stefano and Donisi, Clelia and Spanu, Dario and Pozzari, Marta and Murgia, Sara and Saba, Giorgio and Codipietro, Claudia and Palmas, Enrico and Sanna, Giorgia and Semonella, Francesca and Sardo, Salvatore and Finco, Gabriele and Scartozzi, Mario},
  title = {Early taxane exposure and neurotoxicity in breast cancer patients},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08908-2}
}
Kostenlos starten →